Key clinical point: Upadacitinib can serve as an effective treatment option for atopic dermatitis (AD) and concomitant hand eczema (HE) in daily practice.
Major finding : At week 16, the mean Eczema Area and Severity Index (EASI) score decreased significantly from 17.2 (at baseline) to 4.8 ( P < .001) and 50.0%, 40.6%, 59.3%, and 74.1% of patients achieved EASI-75, an Investigator’s Global Assessment score of (almost) clear, H and Eczema Severity Index-75, and a score of (almost) clear on the photographic guide, respectively. Adverse events were generally mild in severity.
Study details: This multicenter prospective observational study included 38 patients with AD from the BioDay registry who received once-daily upadacitinib over 16 weeks, of which 32 patients had concomitant HE.
Disclosures: The BioDay registry is funded by Sanofi /Regeneron and others . Some authors declared serving as advisors, speakers, or consultants for or receiving consulting fees from various sources, including the registry funders.
Source: Kamphuis E, Loman L, et al. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry. Contact Dermatitis. 2023 (Jan 9). Doi: 10.1111/cod.14276